Topigen Pharmaceuticals Inc. Completes Enrollment of Phase II Clinical Study of TPI ASM8 in Asthma

Published: Jul 23, 2008

MONTREAL--(Marketwire - July 23, 2008) - TOPIGEN Pharmaceuticals Inc., a clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, today announced the completion of patient enrollment in a Phase II safety and efficacy study in asthma with one of its lead product candidates, TPI ASM8. The current clinical study builds on prior efficacy and safety data in a three-day study of TPI ASM8 in an allergen challenge model. TPI ASM8 is a novel, inhaled, anti-inflammatory drug in development for the management of moderate or severe asthma.

Back to news